• Mi Re-Unir
    Búsqueda Avanzada
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Ver ítem 
    •   Inicio
    • RESULTADOS DE INVESTIGACIÓN
    • Artículos Científicos WOS y SCOPUS
    • Ver ítem
    •   Inicio
    • RESULTADOS DE INVESTIGACIÓN
    • Artículos Científicos WOS y SCOPUS
    • Ver ítem

    Advances in hepatitis B therapeutics

    Autor: 
    Soriano, Vicente
    ;
    Barreiro, Pablo
    ;
    Cachay, Edward R.
    ;
    Kottilil, Shyamasundaran
    ;
    Fernandez-Montero, José V.
    ;
    Mendoza, Carmen de
    Fecha: 
    10/2020
    Palabra clave: 
    antiviral therapy; bulevirtide; cccDNA; chronic hepatitis B; combination therapy; gene editing; hepatitis delta; resistance; Emerging; Scopus
    Revista / editorial: 
    Therapeutic Advances in Infectious Disease
    Tipo de Ítem: 
    review
    URI: 
    https://reunir.unir.net/handle/123456789/11112
    DOI: 
    http://doi.org/10.1177/2049936120965027
    Dirección web: 
    https://journals.sagepub.com/doi/10.1177/2049936120965027
    Open Access
    Resumen:
    Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of hepatocellular carcinoma, which represents the third cause of cancer mortality, accounting for nearly 1 million annual deaths. Current oral nucleos(t)ide therapy with tenofovir or entecavir suppresses serum HBV-DNA in most treated patients, but rarely is accompanied by HBsAg loss. Thus, treatment has to be given lifelong to prevent viral rebound. A broad spectrum of antivirals that block the HBV life cycle at different steps are in clinical development, including entry inhibitors, cccDNA disrupters/silencers, translation inhibitors, capsid assembly modulators, polymerase inhibitors and secretion inhibitors. Some of them exhibit higher potency than current oral nucleos(t)ides. Drugs in more advanced stages of clinical development are bulevirtide, JNJ-6379, ABI-H0731, ARO-HBV and REP-2139. To date, only treatment with ARO-HBV and with REP-2139 have resulted in HBsAg loss in a significant proportion of patients. Combination therapies using distinct antivirals and/or immune modulators are expected to maximize treatment benefits. The current goal is to achieve a 'functional cure', with sustained serum HBsAg after drug discontinuation. Ultimately, the goal of HBV therapy will be virus eradication, an achievement that would require the elimination of the cccDNA reservoir within infected hepatocytes.
    Mostrar el registro completo del ítem
    Este ítem aparece en la(s) siguiente(s) colección(es)
    • Artículos Científicos WOS y SCOPUS

    Estadísticas de uso

    Año
    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    2024
    2025
    Vistas
    0
    0
    0
    0
    0
    0
    0
    0
    0
    43
    49
    44
    85
    51
    Descargas
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0

    Ítems relacionados

    Mostrando ítems relacionados por Título, autor o materia.

    • Oral antivirals for the prevention and treatment of SARS-CoV-2 infection 

      Soriano, Vicente; de Mendoza, Carmen; Edagwa, Benson; Treviño, Ana; Barreiro, Pablo; Fernandez-Montero, José V.; Gendelman, Howard E. (AIDS Reviews, 2022)
      Vaccines and antivirals are the classical weapons deployed to contain, prevent, and treat life-threatening viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against severe COVID-19 disease manifestations ...
    • Coronavirus and other airborne agents with pandemic potential 

      Fernandez-Montero, José V.; Soriano, Vicente ; Barreiro, Pablo; de Mendoza, Carmen; Artacho, Miguel Ángel (Current opinion in environmental science and health, 2020)
      The recent emergence of a novel coronavirus (severe acute respiratory syndrome coronavirus 2) has caused a pandemic, which is the most severe infectious disease outbreak in many decades. Other infective agents such as ...
    • Use of antibiotics in respiratory viral infections 

      Fernández-Montero, José Vicente; Corral, Octavio Jorge; Barreiro, Pablo; Soriano, Vicente (Internal and Emergency Medicine, 2022)
      Besides the intrinsic complications caused by SARS-CoV-2 infection, other conditions, such as bacterial infections pose an additional risk to COVID-19 patients. The study published in this issue by Moreno-Torres et al. [1] ...

    Mi cuenta

    AccederRegistrar

    ¿necesitas ayuda?

    Manual de UsuarioContacto: reunir@unir.net

    Listar

    todo Re-UnirComunidades y coleccionesPor fecha de publicaciónAutoresTítulosPalabras claveTipo documentoTipo de accesoEsta colecciónPor fecha de publicaciónAutoresTítulosPalabras claveTipo documentoTipo de acceso






    Aviso Legal Política de Privacidad Política de Cookies Cláusulas legales RGPD
    © UNIR - Universidad Internacional de La Rioja
     
    Aviso Legal Política de Privacidad Política de Cookies Cláusulas legales RGPD
    © UNIR - Universidad Internacional de La Rioja